ASPG and hematopoietic and lymphoid cell neoplasm: The reason for thrombolysis, despite thrombocytopenia, was not mentioned in this case.17 Other than solid malignancies, patients with hematologic cancers are also at dual risk of thrombocytopenia (bone marrow involvement and cytotoxic effects of therapy) and thrombosis (due to cancer itself, endothelial damage secondary to chemotherapy, and asparaginase induced pro-thrombotic state).28 Very few studies have evaluated the effects of AC or thrombolysis in such patients.